Latest Articles
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - MSN
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability MSN
Published: Oct. 30, 2025, 4:04 a.m.
'Doctors misdiagnosed me with cancer — they apologized after my hysterectomy' - MSN
'Doctors misdiagnosed me with cancer — they apologized after my hysterectomy' MSN
Published: Oct. 30, 2025, 2:56 a.m.
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging - springermedicine.com
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging springermedicine.com
Published: Oct. 29, 2025, 10:52 p.m.
Early cancer detection, with new tools and genetic testing, saves lives - Qatar Tribune
Early cancer detection, with new tools and genetic testing, saves lives Qatar Tribune
Published: Oct. 29, 2025, 9 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 28, 2025, 5:03 a.m.
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks
Published: Oct. 27, 2025, 11:43 p.m.
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks
Published: Oct. 27, 2025, 10:53 p.m.
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study TipRanks
Published: Oct. 27, 2025, 10:21 p.m.
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks
Published: Oct. 27, 2025, 9:13 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 27, 2025, 7:50 p.m.
Link copied to clipboard!